Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KAPIVARA trial of KD-414 booster after two BNT162b2 doses
jRCTs031210388Completed
- Sponsor
- KM Biologics
- Start
- Nov 2021
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of KD-414 in coronavirus disease 2019 (COVID-19), sponsored by KM Biologics. Primary endpoint: Neutralizing antibody conversion rate at Day 7. Started Nov 2021; status: completed.
02
Drugs
KD-414
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCTs031210388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210388.